PIKAS For Manufacturing Workers To Be Launched In Phase 4
The public-private partnership immunisation program prioritises those in the critical manufacturing sub-sectors.
Subscribe to our Telegram channel for the latest stories and updates.
The Ministry of Science, Technology, and Innovation (MOSTI) and the Ministry of Health (MOH) has agreed to launch the Program Imunisasi Industri Covid-19 Kerjasama Awam-Swasta (PIKAS) as a part of phase 4 of the national Covid-19 Immunisation Program (PICK).
PIKAS will focus on immunising workers in the manufacturing sector. It prioritises those in the critical manufacturing sub-sectors including electrical and electronics, food processing, iron and steel, medical devices, personal protective equipment (PPE), oil and gas, and rubber products including medical glove manufacturing sub-sectors.
The public-private partnership immunisation program is coordinated by the Ministry of International Trade and Industry (MITI). Participation of companies and employees in PIKAS are voluntary.
MITI Minister, Datuk Seri Mohamed Azmin Ali said that the vaccines under PIKAS are free but the process of administering the vaccine is supported by the private sector. It will be implemented nationwide and includes vaccination at the factory premises.
MITI has already received applications from about 500 companies with a total of 106,591 workers to participate in PIKAS.
Priority of vaccination of companies will be based on several considerations including the company’s location in Covid-19 redzones. They are subject to terms and conditions such as employees having registered with MySejahtera under PICK.
The ministry warns employers not to deduct administration fees paid to the private medical general practitioners and for usage of private-run vaccine administration centres from employee’s salary including in cases where the employee is no longer employed by the company before receiving full immunisation of the employee.
PIKAS is set to launch on 16 June.
Share your thoughts with us on TRP’s Facebook, Twitter, and Instagram.
